Exicure Regains Nasdaq Compliance as of July 2025

Exicure ( (XCUR) ) has shared an update.

On August 4, 2025, Exicure, Inc. announced that it regained compliance with Nasdaq’s periodic filing requirements as of July 1, 2025, following the submission of its Form 10-Q for the fiscal quarter ended March 31, 2025. This compliance was confirmed by Nasdaq’s Listing Qualifications Department, resolving the matter and potentially stabilizing the company’s market position.

Spark’s Take on XCUR Stock

According to Spark, TipRanks’ AI Analyst, XCUR is a Neutral.

Exicure’s overall stock score of 47.8 reflects significant financial challenges, including ongoing losses and reliance on external funding. Technical analysis indicates bearish momentum, and the valuation highlights risks due to negative profitability. The lack of earnings call and corporate events data further limits the assessment.

To see Spark’s full report on XCUR stock, click here.

More about Exicure

Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for hematologic diseases. Historically, the company has worked on nucleic acid therapies targeting ribonucleic acid against validated targets. Recently, Exicure underwent restructuring and suspended its clinical and development activities, and is now exploring strategic alternatives to maximize stockholder value.

Average Trading Volume: 103,932

Technical Sentiment Signal: Sell

Current Market Cap: $43.5M

For detailed information about XCUR stock, go to TipRanks’ Stock Analysis page.